Organigram (OGI) Q1 2026 earnings review
Strong YoY Growth Masks Seasonal Drop and Cash Burn
Organigram posted impressive Year-over-Year numbers, with Net Revenue up 49% to $63.5M and Adjusted EBITDA jumping 273% to $5.3M. However, the sequential picture is less rosy: revenue fell 21% from the record Q4 ($80.1M), and International sales nearly halved sequentially. While Net Income hit a positive $20M, this was driven by non-cash fair value adjustments; operationally, the company burned $16M in cash this quarter, drawing liquidity down to $63M.
🐂 Bull Case
Despite lower seasonal volume, Adjusted Gross Margin hit 38% (up from 33% YoY). Operational efficiencies and higher yields (+43% kg harvested) are structural improvements protecting profitability.
Organigram solidified its #1 rank in Canada across key categories: Vapes, Milled Flower, and Concentrates. Defending this lead while integrating Motif Labs proves execution strength.
🐻 Bear Case
Operating Cash Flow (after working capital) was -$16.0M, a sharp deterioration from -$4.2M a year ago. Cash and short-term investments dropped ~25% in a single quarter (from $84.4M to $63.0M).
While up YoY, International revenue dropped significantly from ~$9.7M in Q4 to $5.0M in Q1. This segment is high-margin, so volatility here disproportionately impacts the bottom line.
⚖️ Verdict: ⚪
Neutral. The YoY growth confirms the strategy is working, but the sharp sequential deceleration and $21M cash burn (Total Cash change) in one quarter are sobering. Investors should wait to see if Q2 rebounds from seasonality before chasing the headline growth.
Key Themes
Cash Flow Divergence
A major red flag is the gap between reported Net Income and Cash Flow. The company reported $20.0M Net Income, but this was driven by fair value changes in financial instruments. Real Operating Cash Flow (after working capital) was negative $16.0M. The company burned through over $21M in total liquidity during the quarter.
International Sales Volatility
Decelerating. International sales are the company's margin engine. While the press release highlights a +51% YoY increase, the sequential trend shows a massive drop from the highs of late FY25. This lumpiness makes quarterly earnings hard to predict.
Genetics Breakthrough
Organigram announced a proprietary genetic screening breakthrough for Powdery Mildew resistance. This allows identification of resistant plants in days rather than months. If deployed at scale, this is a significant long-term driver for yield stability and cost reduction, reducing crop loss risks.
US Regulatory Cliff
The company expanded US distribution into Illinois and Wisconsin. However, the 'Risk Factors' note regarding the US Farm Bill amendment (effective Nov 2026) threatens the entire hemp-derived THC business model. If not repealed or amended, Organigram may have to wind down US operations, putting recent investments at risk.
Synergies Driving Gross Margin
Accelerating. Adjusted Gross Margin reached 38%, up from 33% a year ago. Management cites operational efficiencies, higher yields, and Motif integration synergies. Maintaining high-30s margins during a seasonally low revenue quarter is a strong signal of underlying operational health.
Other KPIs
Accelerating YoY. Up 273% from $1.4M in 25Q1. This marks a continuation of positive EBITDA generation, although it stepped down from the record $9.8M seen in 25Q4 due to lower seasonal revenue.
Accelerating. Production output increased 43% YoY. The company attributes this to nutrient and environmental enhancements, leading to lower per-unit costs. This volume capability supports the aggression in international expansion.
Stable. While the absolute number increased 41% YoY due to the Motif acquisition, SG&A as a percentage of net revenue actually improved (declined) to 38% from 40% a year ago, demonstrating operating leverage.
Guidance
Stable/Accelerating. Management states they 'project further international sales growth' throughout FY2026. No specific range provided, but the direction is positive despite the Q1 dip.
Stable. CFO expects the elevated margin trend (38%) to continue throughout Fiscal 2026, driven by efficiency and synergies. This aligns with prior targets of approaching 40%.
Delayed/Ongoing. The company is still 'awaiting confirmation' or next steps after providing feedback in Jan 2026. This certification is critical for higher-margin European shipments; the lack of a firm date is a continued drag.
Key Questions
Cash Burn Runway
You burned ~$21M in total liquidity this quarter (Cash + Short Term Investments drop). With $63M remaining and negative working capital trends, do you anticipate needing to raise capital in FY26?
International Seasonality vs. Trend
International sales dropped 50% sequentially (from ~$9.7M to $5.0M). Is this purely timing of shipments, or have you seen a change in demand from key partners like Sanity Group?
US Strategy Contingency
With the US Farm Bill amendment looming in Nov 2026, what is the specific contingency plan for the US beverage division if the ban on hemp-derived THC is implemented?